The company shared data at the Association for Research in Vision and Ophthalmology annual meeting in New Orleans that demonstrated that a single oral dose of D-4517.2 significantly reduced choroidal neovascularization lesions to a level comparable to D-4517.2 delivered subcutaneously and aflibercept administered intravitreally at the same mass dose in a laser-induced CNV mouse model.
Ashvattha Therapeutics this week announced two preclinical data sets demonstrating the efficacy of its anti-angiogenic precision nanomedicine, D-4517.2.
The data were shared in an oral presentation and poster at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting held in New Orleans.
According to the company, D-4517.2 is a novel precision nanomedicine that inhibits neovascularization by targeting activated microglia and hypertrophic retinal pigment cells, cells responsible for the increased vascularization associated with neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
“Patients suffering from wet AMD and DME often have to endure injections directly into the eye at a specialist’s office in order to find any relief,” said Jeff Cleland, CEO, co-founder, and chairman of Ashvattha.
Cleland also pointed out the data supports the development of an oral formulation of D-4517.2 as an alternative to injections while greatly reducing the treatment burden on patients.
“The preclinical data also builds on previous findings that demonstrate our precision nanomedicines selectively target regions of inflammation at a cellular level and cross biological barriers including the blood-retinal barrier,” he said.
Natacha Le Moan, Ph, Head of Translational Sciences at Ashvattha gave an oral presentation titled “Oral Formulation Development of the Anti-Angiogenesis Drug D-4517.2 to Treat Age-related Macular Degeneration (wet AMD) and Diabetic Macular Edema (DME)” in which she discussed the efficacy of the oral formulation of D-4517.2 in a mouse model of wet AMD.
Key highlights from presentation:
Elia Duh, a collaborator from Johns Hopkins University presented a poster titled “Suppression of subretinal neovascularization in Vldlr knockout mice by systemic administration of a targeted VEGF-receptor inhibitor,” in which he discussed the cellular localization and efficacy of D-4517.2 in a wet AMD mouse model.
Key highlights from poster presentation: